• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CPRX

CPRX

Catalyst Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD31.28

+0.01 (+0.03%)

Rating:A-

Company Profile

CEO

Richard John Daly

IPO Date

2006-11-08

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$31.26

Prev. Close

$31.27

Day Low

$31.25

Day High

$31.30

52W Low

$19.05

52W High

$32.56

Market Cap

$3.83B

Volume

1.38M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

45.5%

Avg Negative

3.3%

Avg Neutral

50.8%

News Feed

Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

GlobeNewsWire·8/16/2021·↑ positive

Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why

Zacks Investment Research·8/11/2021·↑ positive

Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y

Zacks Investment Research·8/10/2021·↑ positive

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/10/2021·↓ negative

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research·8/9/2021·↑ positive

Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewsWire·8/9/2021·↑ positive

Catalyst Pharmaceutical (CPRX) Reports Next Week: What Awaits?

Zacks Investment Research·8/2/2021·↑ positive

Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021

GlobeNewsWire·7/26/2021·↑ positive

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®

GlobeNewsWire·7/19/2021·↑ positive

Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns

Zacks Investment Research·7/15/2021·↑ positive